{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 53 of 81', 'Reports which will be included in the Clinical Study Report for this study. The bioanalyst will', 'be unblinded for analysis of study samples.', 'The PK calculations will be based on the actual sampling and dosing times. Therefore, it is of', 'importance to have this data thoroughly documented in the eCRF. Deviations from the', 'specified time points will be documented and taken into account when calculating the PK', 'parameters. Those deviations do not qualify as protocol violations.', 'Pharmacokinetics and, if applicable, pharmacokinetics/pharmacodynamics (PK/PD) modeling', 'using population approaches to describe vericiguat PK including potential influence of', 'relevant patient co-variables (e.g., age, gender, body weight, etc.) or potentially to relate', 'parameters of clinical safety and efficacy response (e.g. primary, secondary and/or', 'exploratory variables) with vericiguat plasma concentrations will be investigated under a', 'separate detailed PK/PD evaluation and analysis plan.', '9.6', 'Safety', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including:', 'Primary safety variable:', 'The incidence of treatment-emergent AEs', 'Exploratory safety variables:', 'Vital signs', 'Laboratory data', '12- lead ECG data', '9.6.1', 'Adverse events', '9.6.1.1', 'Definitions', 'Definition of adverse event (AE)', 'In a clinical study, an AE is any untoward medical occurrence (i.e. any unfavorable and', 'unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or', 'clinical investigation patient after providing written informed consent for participation in the', 'study. Therefore, an AE may or may not be temporally or causally associated with the use of a', 'medicinal (investigational) product.', 'A surgical procedure that was planned prior to the start of the study by any physician treating', 'the patient should not be recorded as an AE (however, the condition for which the surgery is', 'required may be an AE).', 'In the following differentiation between medical history and AEs, the term \"condition\" may', 'include abnormal e.g. physical examination findings, symptoms, diseases, laboratory, ECG.']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 54 of 81', 'Conditions that started before signing of informed consent and for which no symptoms', 'or treatment are present until signing of informed consent are recorded as medical', 'history (e.g. seasonal allergy without acute complaints).', 'Conditions that started before signing of informed consent and for which symptoms or', 'treatment are present after signing of informed consent, at unchanged intensity, are', 'recorded as medical history (e.g. allergic pollinosis).', 'Conditions that started or deteriorated after signing of informed consent will be', 'documented as adverse events. This includes intercurrent illnesses.', 'Definition of serious adverse event (SAE)', 'An SAE is classified as any untoward medical occurrence that, at any dose, meets any of the', 'following criteria (a - f):', 'a. Results in death', 'b. Is life-threatening', 'The term \"life-threatening\\' in the definition refers to an event in which the patient was', 'at risk of death at the time of the event, it does not refer to an event which', 'hypothetically might have caused death if it were more severe.', 'c. Requires inpatient hospitalization or prolongation of existing hospitalization', 'A hospitalization or prolongation of hospitalization will not be regarded as an SAE if', 'at least one of the following exceptions is met:', '- The admission results in a hospital stay of less than 12 hours', '-', 'The admission is pre-planned', '(e.g. elective or scheduled surgery arranged prior to the start of the study;', 'admission is part of the study procedures as described in Section 9.2)', '-', 'The admission is not associated with an AE', '(e.g. social hospitalization for purposes of respite care).', 'However, it should be noted that invasive treatment during any hospitalization may', 'fulfill the criterion of \"medically important\\' and as such may be reportable as an SAE', 'dependent on clinical judgment. In addition, where local regulatory authorities', 'specifically require a more stringent definition, the local regulation takes precedence.', 'd. Results in persistent or significant disability / incapacity', \"Disability means a substantial disruption of a person's ability to conduct normal life's\", 'functions.', 'e. Is a congenital anomaly / birth defect', 'f. Is another serious or important medical event as judged by the investigator', '9.6.1.2 Classifications for adverse event assessment', 'All AEs will be assessed and documented by the investigator according to the categories', 'detailed below.', '9.6.1.2.1', 'Seriousness', 'For each AE, the seriousness must be determined according to the criteria given in', 'Section 9.6.1.1.']\n\n###\n\n", "completion": "END"}